Top 10 PEG-Chelator Reagents for Radiopharmaceuticals & Diagnostics

Radiopharmaceuticals and molecular diagnostics depend on one critical component that rarely gets the spotlight: the chelating agent. Whether you are developing a lutetium-177 radioligand therapy, a gallium-68 PET tracer, or a gadolinium-based MRI contrast agent, the chelator-PEG linker you choose governs radiolabeling efficiency, serum stability, and biodistribution. A poorly chosen chelating agent can tank an otherwise promising construct — leading to premature metal release, off-target accumulation, and failed IND-enabling studies. This buyer’s guide ranks the ten best PEG-chelator reagents available today and helps you match each product to the right application.

What to Look For in a PEG-Chelator Reagent

Before diving into individual products, here are the five purchasing criteria that separate a good chelating agent from a great one:

1. Chelator Scaffold: DOTA vs. DTPA vs. Specialty Cages

DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) remains the gold standard macrocyclic chelating agent for therapeutic radionuclides like ¹⁷⁷Lu and ⁶⁸Ga due to its exceptional kinetic inertness. DTPA is faster to label but forms less stable complexes, making it suitable for short-lived isotopes like ⁹⁹ᵐTc and ¹¹¹In. Newer scaffolds like DOTAGA offer an extra carboxylic arm for conjugation without sacrificing a chelating donor atom. Match the scaffold to your isotope and application half-life.

2. PEG Spacer Length and Dispersity

The PEG spacer between the chelator and the targeting moiety controls hydrophilicity, reduces immunogenicity, and fine-tunes pharmacokinetics. Critically, monodisperse PEG spacers (a single, defined molecular weight) deliver reproducible hydrodynamic radius and consistent biodistribution from batch to batch. Polydisperse PEG introduces a distribution of chain lengths that broadens your pharmacokinetic profile and complicates regulatory filings. For radiopharmaceutical development — where every microgram matters — monodisperse PEG-chelator conjugates are the clear choice.

3. Reactive Handle Chemistry

Your chelating agent needs a bioconjugation handle compatible with your construct. Common options include NHS esters (amine-reactive), maleimides or bromoacetamides (thiol-reactive), azides and alkynes (click chemistry), and tetrazines (inverse electron-demand Diels–Alder). Choosing the right reactive group simplifies your bioconjugation workflow and preserves binding affinity.

4. Purity and Analytical Documentation

Residual free chelator competes with your conjugate for the radiometal, reducing specific activity. Look for ≥95% purity by HPLC, and ideally 99%+ for clinical-grade work. Full analytical documentation — CoA, mass spec, and HPLC traces — should be available on request.

5. Supply Reliability and Regulatory Track Record

Radiopharmaceutical timelines are tight. Suppliers who stock reagents for next-day shipping, offer custom synthesis, and have a track record in FDA-approved programs reduce project risk. Peer-reviewed citations (e.g., via Bioz) provide additional confidence that a chelating agent performs as advertised.

—

The 10 Best PEG-Chelator Reagents — Ranked

1. PurePEG Chelating Agent Collection (24 Monodisperse Reagents)

Best overall: broadest monodisperse chelator-PEG portfolio

PurePEG’s chelating agent collection spans 24 monodisperse reagents across DOTA, DOTAGA, and protected-DOTA scaffolds. Every product features a defined PEG spacer (PEG3–PEG10) and a precisely characterized molecular weight — no polydispersity, no batch variability. The collection covers all major conjugation chemistries: NHS esters, amines, azides, alkynes, bromoacetamides, and tetrazines.

What sets this collection apart is the combination of structural variety and monodisperse architecture. Researchers can screen spacer lengths and reactive handles within a single supplier’s catalog, confident that each reagent is 95%+ pure and ships from PurePEG’s San Diego facility with next-day delivery. With over 1,433 Bioz citations across the PurePEG portfolio and reagents used in FDA-approved antibody-drug conjugate (ADC) programs, the quality pedigree is unmatched. Custom synthesis is available for non-catalog spacer lengths or scaffolds.

Key specs: 24 products · DOTA / DOTAGA / protected-DOTA · PEG3–PEG10 · Monodisperse · ≥95% purity · Next-day shipping

👉 Browse the full chelating agent collection →

—

2. PurePEG DOTA-PEG4-Alkyne

Best for click chemistry radiolabeling

DOTA-PEG4-alkyne (SKU 613304, MW 617.69) pairs the DOTA macrocycle with a four-unit monodisperse PEG spacer terminated in a terminal alkyne. This makes it the ideal chelating agent for copper-catalyzed azide–alkyne cycloaddition (CuAAC) and strain-promoted click conjugation workflows — the fastest-growing bioconjugation strategies in radiopharmaceutical development.

The PEG4 spacer provides sufficient distance between the chelator and the targeting vector to minimize steric interference with metal coordination, while the monodisperse chain ensures that every conjugate molecule has identical hydrodynamic properties. This is essential for reproducible radiolabeling yields and predictable biodistribution in preclinical imaging studies. The compound ships as a white solid, is stored at −18 °C, and is available in 10 mg and 25 mg quantities.

For researchers building modular heterobifunctional PEG linker architectures — where the chelator module clicks onto a pre-assembled targeting arm — DOTA-PEG4-alkyne delivers the precision that polydisperse alternatives simply cannot.

Key specs: MW 617.69 · C₂₇H₄₇N₅O₁₁ · Monodisperse PEG4 · Terminal alkyne · ≥95% purity · $833–$1,360

👉 View DOTA-PEG4-alkyne →

—

3. PurePEG DOTA-PEG8-Amine (HCl Salt)

Best for amine-coupling with extended pharmacokinetic tuning

DOTA-PEG8-amine, HCl salt (SKU 613008, MW 798.93) delivers the longest standard monodisperse PEG spacer in PurePEG’s chelator lineup, combined with a primary amine reactive handle. The eight-unit ethylene glycol chain substantially increases the hydrodynamic radius of the chelator module, improving aqueous solubility and reducing nonspecific tissue uptake — a persistent challenge in radiopharmaceutical development.

The terminal amine can be conjugated to NHS esters, activated carboxylic acids, isothiocyanates, or carbonyls, making it compatible with virtually any targeting-vector attachment strategy. For radioligand therapy programs evaluating how spacer length affects tumor penetration and renal clearance, this product provides a longer-spacer data point that pairs directly with PurePEG’s shorter PEG3–PEG5 chelator variants for head-to-head comparison. The monodisperse PEG8 architecture (C₃₄H₆₆N₆O₁₅) guarantees a single molecular species — critical when optimizing structure–activity relationships at the microgram scale.

Key specs: MW 798.93 · Monodisperse PEG8 · Primary amine (HCl salt) · ≥95% purity · $638–$950

👉 View DOTA-PEG8-amine →

—

4. PurePEG Bromoacetamido-PEG5-DOTA

Best for site-specific thiol conjugation

Bromoacetamido-PEG5-DOTA (SKU 613705, MW 787.70, CAS 2353410-19-0) is engineered for selective thiol alkylation — the conjugation chemistry of choice when you need site-specific attachment to engineered cysteine residues on antibodies, nanobodies, or peptides. The bromoacetamide group reacts cleanly with free sulfhydryls under mild conditions, forming a stable thioether bond that withstands the harsh conditions of radiolabeling.

The monodisperse PEG5 spacer (C₃₀H₅₅BrN₆O₁₃) provides an optimal balance between spacer length and synthetic accessibility. This chelating agent is particularly valuable for constructing site-specific radioimmunoconjugates where conjugation site, drug-to-antibody ratio, and linker length all need to be precisely controlled. Researchers working on ¹⁷⁷Lu-labeled antibody or peptide constructs will appreciate the batch-to-batch consistency that only a monodisperse PEG architecture can deliver. Refer to PurePEG’s PEG linker selection guide to compare reactive handle options side by side.

Key specs: MW 787.70 · CAS 2353410-19-0 · Monodisperse PEG5 · Bromoacetamide (thiol-reactive) · ≥95% purity · $408–$570

👉 View Bromoacetamido-PEG5-DOTA →

—

5. Macrocyclics DOTA-NHS Ester

Industry gold standard for amine-reactive DOTA labeling

Macrocyclics’ DOTA-NHS ester has been a workhorse in nuclear medicine for two decades. The NHS ester reacts rapidly with lysine amines, and the DOTA scaffold provides kinetic stability for ⁶⁸Ga, ¹⁷⁷Lu, and ⁹⁰Y. Widely cited and used in clinical-stage radiopharmaceuticals.

However, this is a chelator-only product without a PEG spacer. Users who need a defined spacer must add one separately, increasing complexity and cost.

Key specs: DOTA scaffold · NHS ester (amine-reactive) · No PEG spacer · High literature precedent · Multiple size options

—

6. CheMatech DOTA-PEG4-NHS

Established European supplier of PEG-chelator conjugates

CheMatech (Dijon, France) offers DOTA-PEG4-NHS, a chelating agent that combines the DOTA macrocycle with a four-unit PEG spacer and an NHS ester handle. This product has found adoption in European academic labs for ⁶⁸Ga-PET tracer development. CheMatech provides solid analytical documentation and has a strong reputation in the macrocyclic chemistry community.

The main limitation is that CheMatech’s PEG spacers are typically polydisperse at longer chain lengths, and international shipping from France can introduce lead times of 1–2 weeks for North American labs. For researchers needing rapid turnaround and guaranteed monodisperse spacers, PurePEG’s chelator collection provides a faster, more controlled alternative.

Key specs: DOTA scaffold · PEG4 · NHS ester · European supplier · Good academic adoption

—

7. BroadPharm DOTA-PEG-NH2 Series

Wide catalog of azide and amine chelator-PEG variants

BroadPharm offers DOTA-PEG-amine and DOTA-PEG-azide conjugates spanning PEG2 through PEG12, convenient for screening spacer lengths. Azide-terminated variants support DBCO-based click chemistry.

The trade-off: at longer PEG lengths, products may use polydisperse PEG, complicating pharmacokinetic modeling. Purity specs vary by catalog number. Reasonable for discovery screening; for clinical translation, consider monodisperse alternatives.

Key specs: DOTA scaffold · PEG2–PEG12 · Amine or azide handles · Broad catalog · Variable dispersity at longer chain lengths

—

8. Sigma-Aldrich (MilliporeSigma) DTPA Derivatives

Classic acyclic chelators for short-lived isotopes

Sigma-Aldrich’s DTPA derivatives — including p-SCN-Bn-DTPA and DTPA dianhydride — remain go-to chelating agents for ⁹⁹ᵐTc-SPECT and ¹¹¹In labeling. DTPA chelates metals rapidly at room temperature without the heating DOTA requires, advantageous for heat-sensitive biologics.

The downside is kinetic instability: DTPA complexes are prone to transchelation in vivo, making them unsuitable for ¹⁷⁷Lu therapeutics. These are chelator-only reagents without PEG spacers. Researchers developing theranostics will need DOTA-based, PEG-integrated options — such as PurePEG’s chelator collection.

Key specs: DTPA scaffold · Acyclic · Fast radiolabeling · Best for ⁹⁹ᵐTc, ¹¹¹In · No PEG spacer · Broad availability

—

9. AAT Bioquest Chelator Conjugates

Dual-modality: chelation meets fluorescence

AAT Bioquest offers a niche category of chelator conjugates that integrate a metal-binding domain with a fluorescent reporter — enabling dual-modality imaging (optical + nuclear) from a single construct. These products are popular in preclinical research labs developing fluorescence-guided surgery protocols paired with PET or SPECT imaging.

These are specialty reagents best suited for proof-of-concept studies rather than clinical translation. The fluorophore adds molecular weight and hydrophobicity that can alter biodistribution, and the chelator scaffolds are often proprietary rather than the well-characterized DOTA or DTPA frameworks used in approved drugs. For programs focused purely on radiopharmaceutical performance, a dedicated DOTA-PEG chelating agent — without the optical payload — will deliver cleaner data.

Key specs: Chelator + fluorophore · Dual-modality imaging · Preclinical focus · Proprietary scaffolds · Limited PEG options

—

10. BiochemPEG Chelator-PEG Linkers

Budget-friendly option for early discovery

BiochemPEG markets a range of chelator-PEG linkers at price points below most competitors, making them accessible for academic labs operating under tight budgets. The catalog includes DOTA-PEG and NOTA-PEG variants with amine, NHS, and azide functional groups.

Budget pricing comes with trade-offs: limited analytical documentation, unspecified PEG dispersity on some product pages, and lead times of 2–3 weeks for non-stock items. For early-stage target validation, BiochemPEG is a cost-effective entry point. Once a program advances toward GLP studies or IND filing, transitioning to a supplier with verified monodisperse PEG — like PurePEG — becomes essential.

Key specs: DOTA / NOTA scaffolds · Various PEG lengths · Budget pricing · Variable documentation · Longer lead times on some items

—

How to Choose the Right PEG-Chelator Reagent

Selecting the right chelating agent depends on three primary variables: your radioisotope, your conjugation strategy, and your development stage.

Match the chelator to your isotope

Match the reactive handle to your construct

• Lysine-rich proteins → NHS ester or amine handles
• Engineered cysteines → Bromoacetamide (e.g., Bromoacetamido-PEG5-DOTA) or maleimide
• Click chemistry → Alkyne (e.g., DOTA-PEG4-alkyne) or azide
• Pretargeting → Tetrazine / TCO pairs

Match PEG length to your pharmacokinetic goals

Shorter spacers (PEG3–PEG4) minimize molecular weight while still improving solubility. Longer spacers (PEG8–PEG10) increase hydrodynamic radius, extend circulation time, and reduce renal clearance for larger constructs. PurePEG’s chelator catalog lets you screen PEG3 through PEG10 in a monodisperse, head-to-head comparison — a capability most competitors lack. Consult the PEG linker selection guide for detailed spacer-length recommendations.

Prioritize monodisperse PEG for translational programs

For any program headed toward IND filing, monodisperse PEG is not optional — it is a regulatory expectation. Polydisperse PEG introduces a distribution of species that complicates analytical characterization, batch release testing, and pharmacokinetic modeling. Starting with monodisperse reagents from discovery through clinical development avoids costly reformulation later.

—

Frequently Asked Questions

Q: What is the difference between a chelating agent and a chelator-PEG conjugate?

A: A chelating agent is the metal-binding molecule itself (e.g., DOTA or DTPA). A chelator-PEG conjugate integrates that chelating agent with a PEG spacer and a reactive functional group, creating a ready-to-use bioconjugation building block. The PEG spacer improves solubility, reduces immunogenicity, and provides spatial separation between the chelator and the targeting molecule — streamlining synthesis compared to multi-step approaches.

Q: Why does PEG dispersity matter for radiopharmaceuticals?

A: Polydisperse PEG contains a statistical distribution of chain lengths, meaning your final conjugate is actually a mixture of species with different molecular weights and hydrodynamic properties. This heterogeneity broadens pharmacokinetic profiles, complicates dose calculations, and makes batch-to-batch comparison difficult. Monodisperse (discrete) PEG eliminates this variability, giving you a single molecular entity with predictable behavior — exactly what regulators expect in IND and BLA submissions. Learn more about how PEG architecture affects targeted delivery performance.

Q: Can I use a DTPA chelating agent for lutetium-177 therapy?

A: Technically yes, but it is not recommended. DTPA is an acyclic chelator that forms kinetically labile complexes with ¹⁷⁷Lu. Over the 6.6-day half-life of lutetium-177, significant transchelation can occur in vivo, releasing free radiometal that accumulates in bone and other non-target tissues. DOTA-based chelating agents — which form kinetically inert complexes — are the standard of care for ¹⁷⁷Lu radioligand therapy and are used in all FDA-approved ¹⁷⁷Lu radiopharmaceuticals.

Q: How do I choose between an amine-reactive and a thiol-reactive chelating agent?

A: It depends on your conjugation strategy and desired site-specificity. Amine-reactive chelating agents (NHS esters) conjugate to abundant lysine residues, producing a heterogeneous mixture of conjugation sites. Thiol-reactive agents (bromoacetamides, maleimides) target engineered cysteine residues or reduced disulfides, enabling site-specific conjugation with controlled drug-to-antibody ratios. For clinical-stage radioimmunoconjugates, thiol-reactive approaches like Bromoacetamido-PEG5-DOTA are increasingly preferred because they produce more homogeneous products.

—

Ready to Build Better Radiopharmaceuticals?

PurePEG’s chelating agent collection gives you 24 monodisperse DOTA and DOTAGA reagents — the widest selection of defined-length chelator-PEG building blocks available from a single supplier. Every product is manufactured in San Diego, ships next-day, and is backed by full analytical documentation. Whether you need a click-ready alkyne, a site-specific bromoacetamide, or a custom spacer length, PurePEG has you covered.

👉 Explore the full chelating agent catalog →

Need help selecting the right chelating agent for your project? Contact PurePEG’s technical team for a free consultation.